Sulfadoxine Pyrimethamine 175mg + Dihydroartemisinin 60mg

Sulfadoxine‑Pyrimethamine + Dihydroartemisinin Tablets
  • Dosage: Sulfadoxine/Pyrimethamine 175mg and Dihydroartemisinin 60mg
  • Packaging: 9 tablets/blister*10/box
  • Shelf Life: 36months 

Click to add this item to cart.

Product Description

Product NameSulfadoxine/Pyrimethamine + Dihydroartemisinin Tablets (Sulfadoxine/Pyrimethamine 175mg + Dihydroartemisinin 60mg Oral Tablets)
SpecificationEach tablet contains: Sulfadoxine/Pyrimethamine 175mg + Dihydroartemisinin 60mg
Dosage FormOral Film-Coated Tablet (for oral administration)
Active IngredientsSulfadoxine / Pyrimethamine / Dihydroartemisinin
Pharmacological ClassAntimalarial Combination (Sulfonamide / Antifolate / Artemisinin Derivative)
Route of AdministrationOral administration (swallowed whole with water; take with food to reduce gastrointestinal upset). Take at approximately the same time each day during the treatment course.
PackagingBlister pack (PVC-Alu) or strip pack, typically per treatment course
StorageStore below 25°C, in a dry place, protected from light and moisture. Keep container tightly closed. Do not freeze.
Shelf Life36 months (unopened)

Product Overview

This product is an oral antimalarial combination tablet containing Sulfadoxine/Pyrimethamine 175mg and Dihydroartemisinin 60mg per tablet. It combines two classes of antimalarial agents: (a) a long-acting sulfonamide antifolate combination (sulfadoxine/pyrimethamine), and (b) a short-acting artemisinin derivative (dihydroartemisinin). The combination of short-acting and long-acting antimalarial agents is designed to provide rapid parasite clearance while also reducing the risk of parasite resistance development. The product is formulated as film-coated tablets for convenient oral administration.

Sulfadoxine Pyrimethamine 175mg + Dihydroartemisinin 60mg: What the Published Guidance Says

Artemisinin-based combination therapy is the WHO-recommended backbone of falciparum malaria treatment.

Buyers usually settle three things before ordering Sulfadoxine Pyrimethamine 175mg + Dihydroartemisinin 60mg: the pharmacopoeial monograph, the pack configuration, and the documents the destination authority will ask for.

  • The ACT combinations and their strengths are specified on the WHO Model List Section 6.5.3.1 of the 24th WHO Model List (2025) specifies the curative antimalarials, including artemether + lumefantrine tablet 20 mg + 120 mg and a dispersible tablet, artesunate + amodiaquine, artesunate + mefloquine, artesunate + pyronaridine as granules and tablets, dihydroartemisinin + piperaquine across four tablet strengths, and artesunate co-packaged with sulfadoxine + pyrimethamine. WHO Model List of Essential Medicines, 24th List (2025) — report of the 25th WHO Expert Committee (TRS 1064)
  • ACT is the treatment of choice in all trimesters For uncomplicated P. falciparum malaria, MSF medical guidelines state the treatment of choice in all trimesters is an artemisinin-based combination therapy taken for three days. Co-formulated and co-blistered regimens are both described, including artemether/lumefantrine 20/120 mg and 80/480 mg, artesunate/amodiaquine, artesunate/mefloquine and dihydroartemisinin/piperaquine. MSF Medical Guidelines — Malaria (Chapter 4.3, Parasitic infections)
  • One combination to handle with care MSF notes that the artesunate + sulfadoxine/pyrimethamine combination is contraindicated in HIV-infected women taking co-trimoxazole preventive therapy, and that artesunate/mefloquine should not be used where neurological signs developed during the acute phase. MSF Medical Guidelines — Malaria (Chapter 4.3, Parasitic infections)

These points are quoted because they shape how Sulfadoxine Pyrimethamine 175mg + Dihydroartemisinin 60mg is specified, labelled and purchased — including strength selection, pack size and the artwork wording. Confirm each one against the approved product information in your market before finalising a purchase order.

Sulfadoxine Pyrimethamine 175mg + Dihydroartemisinin 60mg: Specification, Pack & Documentation Summary

Product NameSulfadoxine/Pyrimethamine + Dihydroartemisinin Tablets (Sulfadoxine/Pyrimethamine 175mg + Dihydroartemisinin 60mg Oral Tablets)
SpecificationEach tablet contains: Sulfadoxine/Pyrimethamine 175mg + Dihydroartemisinin 60mg
Dosage FormOral Film-Coated Tablet (for oral administration)
Active IngredientsSulfadoxine / Pyrimethamine / Dihydroartemisinin
Pharmacological ClassAntimalarial Combination (Sulfonamide / Antifolate / Artemisinin Derivative)
Route of AdministrationOral administration (swallowed whole with water; take with food to reduce gastrointestinal upset). Take at approximately the same time each day during the treatment course.
StorageStore below 25°C, in a dry place, protected from light and moisture. Keep container tightly closed. Do not freeze.
Therapeutic groupMalaria & ACTs — Malaria & ACTs
ManufacturerSinophare Bio-technology Co., Ltd. (GMP, China)
Documentation suppliedCOA, HPLC/GC data, stability data, dossier package

The same therapeutic range is supplied in several presentations, so one purchase order can cover a mixed requirement: Chloroquine Phosphate 500mg Tablets, Dihydroartemisinin 40mg + Piperaquine 320mg Tablets, Sulfadoxine/Pyrimethamine 175mg + Amodiaquine 75mg, Artesunate 200mg + Amodiaquine 600mg Tablets, Artesunate 400mg Mefloquine 500mg Tablets, Artemether Lumefantrine 80/480mg Tablets, Artesunate Suppositories 100mg, Artemether 80mg Injection.

How Sulfadoxine Pyrimethamine 175mg + Dihydroartemisinin 60mg Is Tested and Released

Products are manufactured and tested against USP, EP, BP and CP monographs, with incoming raw-material inspection, in-process monitoring and full finished-product testing.

Sulfadoxine Pyrimethamine 175mg + Dihydroartemisinin 60mg is released against the pharmacopoeial monograph named on your order (USP, EP, BP or CP). Where no monograph exists for the exact presentation, the specification is agreed with you in writing before manufacture and is attached to the certificate of analysis.

Standardised GMP production workshops with an independent R&D laboratory and a complete quality-inspection centre.

Release testing on this presentation is built around:

  • Testing for sterility and bacterial endotoxins (parenterals and ophthalmics)
  • Testing for microbial limits and preservative efficacy (multi-dose presentations)
  • Testing for heavy metals and elemental impurities
  • Testing for packaging integrity and seal testing
  • Testing for description and identification
  • Testing for assay of the active substance

COA, HPLC and GC data, DMF and dossier packages, plus registration support documents for national marketing-authorisation filings.

How Sulfadoxine Pyrimethamine 175mg + Dihydroartemisinin 60mg Is Packed, Labelled and Shipped

  • Pack size: Blister pack (PVC-Alu) or strip pack, typically per treatment course. Non-standard pack sizes can be quoted against your artwork.
  • Storage: Store below 25°C, in a dry place, protected from light and moisture. Keep container tightly closed. Do not freeze..
  • Shelf life: 36 months (unopened). Stability data for the marketed pack is included in the dossier.
  • Labelling: artwork can be produced in English, Arabic, French, Russian and Spanish, with your own brand and language mix, subject to the labelling rules of the destination market.
  • Export: GMP certificate, COA, certificate of origin, packing list and, where required, the free-sale or marketing authorisation certificate from the country of manufacture.

Regulatory Support for Sulfadoxine Pyrimethamine 175mg + Dihydroartemisinin 60mg

Sinophare Bio-technology Co., Ltd. holds DML Number Jin20160068 (medicines) and Jin20160069 (paracetamol API).. That registration identifies the legal manufacturer on the certificate of analysis, the GMP certificate and the documents filed with your national medicines authority.

  • Batch manufacturing and packaging records released for inspection on request during supplier audits.
  • Re-test or renewal support when the marketing authorisation comes up for variation or renewal.
  • CTD dossier modules 1–5 in editable and PDF form, with the finished-product and API sections cross-referenced.
  • Site Master File and GMP certificate for the manufacturing workshops.
  • Method validation, stability protocol and the shelf-life justification for the marketed pack.

This page describes Sulfadoxine Pyrimethamine 175mg + Dihydroartemisinin 60mg as a product of the ACT regimens named in the WHO Model List of Essential Medicines family. A WHO or national listing is a supply-context fact, not an approval in your market; marketing authorisation remains specific to each country.

Questions We Are Asked About Sulfadoxine Pyrimethamine 175mg + Dihydroartemisinin 60mg

What pack size is available for Sulfadoxine Pyrimethamine 175mg + Dihydroartemisinin 60mg?

The reference pack is Blister pack (PVC-Alu) or strip pack, typically per treatment course. Non-standard blister, bottle and carton configurations are quoted against your artwork, matched to the stability data already held for the presentation.

What documentation comes with a shipment of Sulfadoxine Pyrimethamine 175mg + Dihydroartemisinin 60mg?

Each batch ships with a certificate of analysis covering description, identification, assay and related substances, plus stability data for the marketed pack and the GMP certificate of the manufacturing site. Shelf life: 36 months.

Does the batch documentation for Sulfadoxine Pyrimethamine 175mg + Dihydroartemisinin 60mg support a registration filing?

Each batch ships with a certificate of analysis covering description, identification, assay and related substances, plus stability data for the marketed pack and the GMP certificate of the manufacturing site. Shelf life: 36 months. The full CTD dossier and the authority assessment file are supplied as part of a registration order; routine shipments carry the COA and stability data only.

Do you supply dispersible paediatric ACTs?

Yes. We supply dispersible and dry-suspension presentations aligned to the strengths in the Model List, including artemether + lumefantrine 20/120 mg dispersible tablets and paediatric suspensions.

Can you support registration in my market?

We provide COA, HPLC and GC analytical data, stability data, DMF and dossier packages together with registration support documents. DML Number Jin20160068 covers our medicines production.

Companion Products — Malaria & ACTs

Browse the full Malaria & ACTs range; all Tablets; the complete product catalogue.

Request a Quotation for Sulfadoxine Pyrimethamine 175mg + Dihydroartemisinin 60mg

Send the specification, pack size, quantity and destination market for Sulfadoxine Pyrimethamine 175mg + Dihydroartemisinin 60mg 175mg and we will confirm availability, lead time and documentation. Tender quantities and registration samples are handled on the same quotation.

Request a quotation

Sources & Regulatory Notes

Reference information only. The published guidance summarised on this page is quoted for professional and regulatory-context purposes and does not constitute medical advice, a prescribing recommendation or a promotion of any product for a particular indication. Prescribing decisions must follow the approved product information and national treatment guidelines in the market of use.

<< return to products